Nothing Special   »   [go: up one dir, main page]

MX2021003826A - Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. - Google Patents

Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.

Info

Publication number
MX2021003826A
MX2021003826A MX2021003826A MX2021003826A MX2021003826A MX 2021003826 A MX2021003826 A MX 2021003826A MX 2021003826 A MX2021003826 A MX 2021003826A MX 2021003826 A MX2021003826 A MX 2021003826A MX 2021003826 A MX2021003826 A MX 2021003826A
Authority
MX
Mexico
Prior art keywords
benralizumab
methods
asthmatics
expiratory volume
forced expiratory
Prior art date
Application number
MX2021003826A
Other languages
English (en)
Inventor
Lorin Roskos
Christine Ward
Donald Raible
Bing Wang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021003826A publication Critical patent/MX2021003826A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)

Abstract

Se presentan métodos para aumentar el volumen espiratorio forzado en un segundo (FEV1) en un paciente con asma, que comprenden administrar al paciente una cantidad efectiva de benralizumab o un fragmento de unión al antígeno de este.
MX2021003826A 2013-08-12 2016-01-29 Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. MX2021003826A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12

Publications (1)

Publication Number Publication Date
MX2021003826A true MX2021003826A (es) 2021-05-27

Family

ID=52448838

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001384A MX2016001384A (es) 2013-08-12 2014-08-07 Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab.
MX2021003826A MX2021003826A (es) 2013-08-12 2016-01-29 Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016001384A MX2016001384A (es) 2013-08-12 2014-08-07 Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab.

Country Status (26)

Country Link
US (1) US9441046B2 (es)
EP (3) EP3033104B1 (es)
JP (4) JP6746496B2 (es)
KR (1) KR102337599B1 (es)
CN (2) CN111588849A (es)
AU (2) AU2014306959B2 (es)
BR (1) BR112016002317A8 (es)
CA (1) CA2917603C (es)
CY (2) CY1122033T1 (es)
DK (2) DK3033104T3 (es)
ES (2) ES2866426T3 (es)
HK (2) HK1222559A1 (es)
HR (2) HRP20190920T1 (es)
HU (2) HUE053627T2 (es)
LT (2) LT3033104T (es)
ME (1) ME03403B (es)
MX (2) MX2016001384A (es)
PL (2) PL3033104T3 (es)
PT (2) PT3520811T (es)
RS (2) RS61565B1 (es)
RU (1) RU2703568C2 (es)
SG (1) SG11201600483QA (es)
SI (2) SI3520811T1 (es)
SM (2) SMT201900311T1 (es)
TR (1) TR201907907T4 (es)
WO (1) WO2015023507A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057065T2 (hu) 2013-08-12 2022-04-28 Astrazeneca Ab Eljárások asztma tüneteinek javítására benralizumab alkalmazásával
BR112016002401A8 (pt) 2013-08-12 2018-06-12 Medimmune Llc Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CN105611938B (zh) * 2013-10-24 2024-12-31 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010354A1 (en) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1266663A4 (en) 2000-02-15 2003-07-23 Kyowa Hakko Kogyo Kk EOSINOPHILE SPECIFIC APOPTOSE INDUCTORS
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
CN103223167B (zh) * 2007-05-14 2015-06-17 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
SG190885A1 (en) * 2010-12-16 2013-07-31 Genentech Inc Diagnosis and treatments relating to th2 inhibition
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
US8961965B2 (en) 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
KR20140097217A (ko) 2011-11-01 2014-08-06 메디뮨 엘엘씨 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법
BR112016002401A8 (pt) 2013-08-12 2018-06-12 Medimmune Llc Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
HUE057065T2 (hu) 2013-08-12 2022-04-28 Astrazeneca Ab Eljárások asztma tüneteinek javítására benralizumab alkalmazásával

Also Published As

Publication number Publication date
HRP20210406T1 (hr) 2021-04-30
AU2014306959A1 (en) 2016-02-04
CY1124399T1 (el) 2022-07-22
LT3033104T (lt) 2019-06-25
DK3520811T3 (da) 2021-03-22
MX2016001384A (es) 2016-08-03
JP2016527325A (ja) 2016-09-08
EP3033104A4 (en) 2017-03-22
EP3520811B1 (en) 2020-12-30
RU2703568C2 (ru) 2019-10-21
US9441046B2 (en) 2016-09-13
HK1225300A1 (zh) 2017-09-08
WO2015023507A2 (en) 2015-02-19
PT3033104T (pt) 2019-06-27
HUE043497T2 (hu) 2019-08-28
KR102337599B1 (ko) 2021-12-10
CA2917603C (en) 2023-05-16
HRP20190920T1 (hr) 2019-07-12
EP3875487A1 (en) 2021-09-08
US20150044203A1 (en) 2015-02-12
AU2020201277A1 (en) 2020-03-12
CY1122033T1 (el) 2020-10-14
SI3033104T1 (sl) 2019-06-28
CA2917603A1 (en) 2015-02-19
HUE053627T2 (hu) 2021-07-28
EP3033104B1 (en) 2019-04-03
WO2015023507A8 (en) 2015-09-24
JP6746496B2 (ja) 2020-08-26
ME03403B (me) 2020-01-20
JP2024129140A (ja) 2024-09-26
RS61565B1 (sr) 2021-04-29
PT3520811T (pt) 2021-03-15
TR201907907T4 (tr) 2019-06-21
EP3033104A2 (en) 2016-06-22
RU2016108809A3 (es) 2018-06-18
SG11201600483QA (en) 2016-02-26
RS58711B1 (sr) 2019-06-28
ES2733602T3 (es) 2019-12-02
SI3520811T1 (sl) 2021-04-30
HK1222559A1 (zh) 2017-07-07
JP2020125304A (ja) 2020-08-20
ES2866426T3 (es) 2021-10-19
CN105451769A (zh) 2016-03-30
BR112016002317A2 (pt) 2017-12-12
CN111588849A (zh) 2020-08-28
DK3033104T3 (da) 2019-06-17
PL3520811T3 (pl) 2021-08-02
SMT201900311T1 (it) 2019-07-11
RU2016108809A (ru) 2017-09-18
WO2015023507A3 (en) 2015-04-09
KR20160043049A (ko) 2016-04-20
AU2014306959B2 (en) 2019-11-21
BR112016002317A8 (pt) 2018-06-12
JP2022120010A (ja) 2022-08-17
LT3520811T (lt) 2021-03-25
SMT202100152T1 (it) 2021-05-07
EP3520811A1 (en) 2019-08-07
PL3033104T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MY195289A (en) Anti IL-36R Antibodies
PH12015502087B1 (en) Newcastle disease viruses and uses thereof
AU2011328009A8 (en) Compounds and methods for treating pain
PH12015500196B1 (en) Methods of treating a tauopathy
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EP2582722A4 (en) ANTIBODIES AGAINST GD2
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
AU2014306956B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
NZ616048A (en) Administration of iloprost as aerosol bolus
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
WO2014146111A3 (en) Analgesic compounds and methods of use
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
UA103987C2 (ru) Способ терновской т.а. лечения варикозной болезни детей